Patents Assigned to Sanofi Pasteur Inc.
-
Patent number: 11970690Abstract: The present disclosure is directed to a method for cultivating a Bordetella species, comprising: cultivating a Bordetella species under aerobic conditions in a liquid culture medium; and maintaining a pH of the liquid culture medium by using a strong acid, such as nitric acid, or using a first and second acid, wherein the first acid is an inorganic acid that dissociates essentially completely in water, such as nitric acid, hydrochloric acid or sulfuric acid, and wherein the second acid is an inorganic acid having an acid dissociation constant (pKa) of greater than 1, such as phosphoric acid. Methods for increasing the yield of Bordetella fimbrial agglutinogen 2 and fimbrial agglutinogen 3 (FIM2/3) in a supernatant fraction from a Bordetella culture are also provided.Type: GrantFiled: March 19, 2019Date of Patent: April 30, 2024Assignee: SANOFI PASTEUR INC.Inventors: Patrick Farrell, Bo Zhi Sun, Fabien Barbirato, Javier de Jesus Menendez Diaz, Andrew Chiappetta
-
Patent number: 11911452Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: September 10, 2021Date of Patent: February 27, 2024Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
-
Patent number: 11904012Abstract: The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.Type: GrantFiled: August 12, 2021Date of Patent: February 20, 2024Assignee: SANOFI PASTEUR INC.Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen
-
Publication number: 20240016918Abstract: Provided are novel vaccines for prophylactic treatment of SARS-CoV-2 infections and COVID-19 and methods of making the vaccines.Type: ApplicationFiled: August 23, 2021Publication date: January 18, 2024Applicant: SANOFI PASTEUR INC.Inventors: Natalie ANOSOVA, Salvador Fernando AUSAR, Catherine BERRY, Florence BOUDET, Danilo CASIMIRO, Roman M. CHICZ, Gustavo DAYAN, Guy DE BRUYN, Carlos DIAZGRANADOS, Tong-Ming FU, Marie GARINOT, Lorry GRADY, Sanjay GURUNATHAN, Kirill KALNIN, Nikolai KHRAMTSOV, Valérie LECOUTURIER, Nausheen RAHMAN, Sophie RUIZ, Stephen SAVARINO, Saranya SRIDHAR, Indresh K. SRIVASTAVA, James TARTAGLIA, Timothy TIBBITTS
-
Patent number: 11827668Abstract: The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers. Also provided are methods of preparing an influenza vaccine composition using the optimized nucleotide sequences, as well as methods of inducing an immune response using the influenza vaccine composition.Type: GrantFiled: July 19, 2022Date of Patent: November 28, 2023Assignee: SANOFI PASTEUR INC.Inventors: Tod Dwayne Strugnell, Guadalupe Cortes-Garcia, Tim Alefantis
-
Publication number: 20230310567Abstract: Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.Type: ApplicationFiled: June 7, 2023Publication date: October 5, 2023Applicant: Sanofi Pasteur Inc.Inventors: Richard David Kensinger, JR., Steven L. Hauser
-
Patent number: 11707514Abstract: Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.Type: GrantFiled: September 8, 2021Date of Patent: July 25, 2023Assignee: Sanofi Pasteur Inc.Inventors: Richard David Kensinger, Jr., Steven L. Hauser
-
Publication number: 20230121059Abstract: Disclosed herein are immunogenic compositions and vaccination regimes for immunizing humans against influenza disease.Type: ApplicationFiled: February 26, 2021Publication date: April 20, 2023Applicant: Sanofi Pasteur Inc.Inventors: Lee-Jah Chang, Victoria Landolfi, Therese Quinn
-
Patent number: 11576964Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant hemagglutinin (HA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant HA polypeptides.Type: GrantFiled: March 27, 2019Date of Patent: February 14, 2023Assignee: Sanofi Pasteur Inc.Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen, Thorsten Vogel, Harold Kleanthous
-
Patent number: 11427619Abstract: The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers. Also provided are methods of preparing an influenza vaccine composition using the optimized nucleotide sequences, as well as methods of inducing an immune response using the influenza vaccine composition.Type: GrantFiled: January 12, 2021Date of Patent: August 30, 2022Assignee: SANOFI PASTEUR INC.Inventors: Tod Dwayne Strugnell, Guadalupe Cortes-Garcia, Tim Alefantis
-
Patent number: 11419930Abstract: This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.Type: GrantFiled: January 8, 2021Date of Patent: August 23, 2022Assignee: Sanofi Pasteur, Inc.Inventors: Patricia Pietrobon, Ginamarie Foglia, Guy De Bruyn, Sanjay Gurunathan
-
Patent number: 11325947Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.Type: GrantFiled: January 24, 2020Date of Patent: May 10, 2022Assignee: SANOFI PASTEUR INC.Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen
-
Patent number: 11305005Abstract: This application relates to the field of prevention of pneumonia by administration of a high-dose influenza vaccine.Type: GrantFiled: June 23, 2016Date of Patent: April 19, 2022Assignee: SANOFI PASTEUR INC.Inventors: Carlos DiazGranados, Andrew Dunning
-
Patent number: 11286465Abstract: Methods and compositions for increasing the production of recombinant proteins by introducing ICP0 to cells capable of producing a recombinant protein are encompassed. In one method, the recombinant protein is a protein that is required for the replication of a replication defective virus, wherein the recombinant protein is provided to the replication defective virus in trans.Type: GrantFiled: December 21, 2018Date of Patent: March 29, 2022Assignee: SANOFI PASTEUR INC.Inventors: Simon Delagrave, CharChang Lai
-
Patent number: 11241489Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 20 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRMig7, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: August 4, 2017Date of Patent: February 8, 2022Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Wooyoung Choi, Dongsoo Ham, Hun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Eric Desauziers, Clotilde El Guerche Seblain, Philippe Talaga
-
Publication number: 20220031829Abstract: Provided herein are compounds, compositions, formulations, kits, uses, and methods for immunization against Neisseria meningitidis serogroups A, C, Y, and W-135 and human papilloma virus.Type: ApplicationFiled: September 27, 2019Publication date: February 3, 2022Applicant: Sanofi Pasteur Inc.Inventors: Richard David Kensinger, Jr., Steven L. Hauser, Emilia Ivanova Jordanov, Mandeep Singh Dhingra, David Neveu
-
Patent number: 11224652Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM197, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: August 4, 2017Date of Patent: January 18, 2022Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Wooyoung Choi, Dongsoo Ham, Hun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Eric Desauziers, Clotilde El Guerche Seblain, Philippe Talaga
-
Publication number: 20210401964Abstract: Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.Type: ApplicationFiled: September 8, 2021Publication date: December 30, 2021Applicant: Sanofi Pasteur Inc.Inventors: Richard David Kensinger, JR., Steven L. Hauser
-
Patent number: 11147864Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of serotypes two of serotypes 1, 3, and 5 are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: February 4, 2019Date of Patent: October 19, 2021Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
-
Patent number: 11147866Abstract: Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.Type: GrantFiled: February 21, 2019Date of Patent: October 19, 2021Assignee: Sanofi Pasteur Inc.Inventors: Richard David Kensinger, Jr., Steven L. Hauser